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atinine of >25% from baseline during this 96 hour period. The trial was powered to detect 
a reduction in the primary endpoint from 30% to 15%. Secondary endpoints included 
hospital length of stay, adverse cardiac events, re-hospitalization and need for dialysis 
within 30 days. 
Results. In the pooled population, mean age was 70 + 11 years, 34% were female, 51% 
had diabetes, 67% hypertension, 50% prior MI, and 48% prior CHF. The baseline CrCl 
was 29.2 + 10.1 cc/min (range 7.5-57.5). Mean contrast dose was 164 ?; 155 cc. The 
mean hospital length of stay was 4.0 -+ 5.9 days. Within 30 days, 2.3% required dialysis, 
19.2% were re-hospitalized, and 3.2% of pts died. CIN within 24-96 hours of drug, the pri- 
mary endpoint, occurred in 30.5% of pts. 
Conclusfons. Desvite hvdration and contemoorarv catheterization techniaues. CIN is _ . 
common after invasive cardiac procedures in a population with baseline renal insuff- 
ciencv and oortends a ooor oroonosis. The results of CONTRAST. which examined the 
I  . _  
utility of fenoldopam mesylate. a specific Dl agonist, for the prevention of CIN will be 
unblinded for the first time for presentation in March 2003. 
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88OFO-4 lntracoronary Beta-Blocker Protects the Distal 
Myocardium During Percutaneous Coronary 
Intervention 
Fen Wei Wang, Abdulfatah Osman, Javier Otero, George A. Stouffer, Sergio Waxman, 
Adnan Afzal, Angelo Anzuini, BarN F. Uretsky, The University of Texas Medical Branch, 
Galveston, TX 
Background: Experimental studies have shown that IV beta blockers given before coro- 
nary artery occlusion significantly reduce myocardial injury. We tested the hypothesis 
that intracoronary (C) propranolol(O.015 mgikg) pre-coronary intervention (PCI) reduces 
myocardial necrosis (Ml) and short-term adverse outcomes after PCI. Methods Patients 
(n=150) undergoing elective or urgent PCI were randomly assigned in a prospective dou- 
ble-blind fashion to receive either IC propranolol (n=75) or placebo (n=75). Results 
Major adverse events through the first 30 days are shown in the table and figure. Con- 
clusion: lntracoronary administration of propranolol significantly reduces the incidence 
of Ml after PCI, improves short-term clinical outcomes, and suggests its routine use dur- 
ing PCI. 
30 day Results (% of patients) 
Propranolol (n=75) Placebo (n=75) P value 
Elevated CK-MB 17 36 0.01 
Elevated Troponin T 13 33 0.005 
Death 0 0 NS 
Recurrent Ml 1 3 NS 
Urgent TLR 0 3 NS 
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88OFO-5 Marked Survival Benefit Associated With Statin 
Pretreatment Prior to Percutaneous Coronary 
Intervention Is Dependent Upon the Preprocedural 
Inflammatory Status 
Albert W. Ghan Deepak L. Bhan. Derek P. Chew, Joel Reginelli, Deepak P. 
Vivekananthan. Jakob P. Schneider, Eric J. Topol, Stephen G. Ellis, The Ochsner Clinic 
Foundation, New Orleans, LA, The Cleveland Clinic Foundation, Cleveland, OH 
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periprocedural myocardial infarction (MI, 5.7% vs 6.1% P=O.O36). At 1 year, statin pre- 
treatment was predictive of survival almost exclusively among patients within the highest 
CRP quartfle (CRP >l.ll mg/dL) (Figure). In multivariate analysis, the interaction 
between CRP quartiles and statin use remained significant (P=O.O14). After adjusting for 
the propensity of receiving statin, statin pretreatment was an independent predictor for l- 
year survival within the highest CRP quartile (H&0.44, P=O.O39). 
Conclusions: Statin therapy prior to PCI is associated with a marked survival benefit 
among patients with high CRP levels, suggesting mechanism tied to a particular anti- 
inflammatory effect. 
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88OFO-6 Prophylactic Acetylcysteine Is Not Effective in 
Preventing Contrast-Induced Nephropathy Following 
Coronary Angiography 
J. Bradlev Oldernever, Erica K. Cichowski, Richard L. Wurdeman, Kathleen A. Packard, 
W. Paul Biddle, Aryan N. Mooss, Creighton University Medical Center, Omaha, NE 
Background: Contrast-Induced Nephropathy (CIN) is associated with significant morbid- 
ity and mortality following coronary angiography. Oral acetylcysteine at a dose of 600 mg 
every twelve hours has had inconsistent results in preventing CIN following contrast 
administration in previously published reports. 
Methods: 96 patients with a creatinine clearance of 50 mllmin or less were randomized 
in a double blinded manner the evening prior to coronary angiography to receive four 
doses of acetylcysteine 1500 mg every twelve hours versus placebo. All patients 
received t/2 normal saline at 1 mlIkg for 12 hours before and 12 hours after angiography. 
CIN was defined as an increase from the baseline serum creatinine (SC) at 46 hours by 
25% or 0.5 mgldl. Multivariate analysis was utilized to identify the incidence of CIN as 
well as the absolute change in SC at 48 hours. 
Results: Baseline characteristics in the groups were similar, with a mean baseline SC of 
1.64 mg/dl. CIN developed in 4 of 49 (6.2%) patients in the acetylcysteine group and 3 of 
47 (6.4%) in the placebo group (p=O.74). Volume of contrast was similar between the two 
groups: 134 ml in the acetylcysteine group and 127 ml in the placebo group (p=O.63). 
The mean change in the SC from baseline and at 46 hours following contrast exposure 
was -0.01 mgldl in the acetylcysteine group and -0.05 mgldl in the placebo group 
(p=O.52). Multiple variables were analyzed with regards to mean change in SC at 48 
hours. The only significant covariate was the volume of contrast dye delivered (p=O.O3). 
There was no benefit of acetylcysteine on change in SC at 46 hours regardless of the 
severity of renal insufficiency. Acetylcysteine was tolerated as well as placebo. 
Conclusion: Acetylcysteine does not appear to prevent CIN in patients with a creatinine 
clearance less than 50 mg/dl who are undergoing coronary angiography. The volume of 
dye delivered continues to be recognized as a potent factor in the deterioration of kidney 
function following angiography. 
Background: Beyond lipid-lowering, statins possess anti-inflammatory and anti-throm- 
botic effects. The relation between statin therapy and lowering of death/Ml early after 
percutaneous coronary intervention (PCI) has been recently shown. We examined the 
inter-relationship of inflammation, statin use. and PCI outcome. 
Methods: Within the year 2000, 1,552 consecutive patients underwent elective/urgent 
PCI at the Cleveland Clinic and were prospectively followed. Pre-procedural serum high- 
sensitivity C-reactive protein (CRP) levels were measured. Comparisons were made 
between patients with and without statin pretreatment. 
Results: Statin-users (39.6%) had a lower median CRP level (0.40 mg/dl vs 0.50 mg/dl, 
P=O.O12) independent of the baseline cholesterol levels, and had less incidence of 
